Long-acting HIV Pre-Exposure Prophylaxis Integrated With Community-based Sexual and Reproductive Health in South Africa (LAPIS): A Hybrid (1a) Cluster Randomised Controlled Phase 3B Trial of Effectiveness and Implementation

The goal of this hybrid (1a) Cluster Randomised Controlled Trial phase 3B trial is to evaluate the effectiveness and implementation of offering a choice of HIV Pre-Exposure Products (PrEP) through community-based sexual and reproductive health services, on PrEP uptake and retention, and population prevalence of sexually transmissible HIV amongst adolescents and young adults living in rural South Africa.
Researchers will compare adding the choice of long-acting PrEP, i.e. two monthly injectable cabotegravir (CAB LA) or dapiravine vaginal ring and HIV post exposure prophylaxis packs to daily oral PrEP integrated with community-based SRH in the 20 intervention clusters with standard of care (SoC), daily oral PrEP integrated with community-based SRH in the 20 control clusters, on uptake and retention on PrEP. We hypothesise that offering a choice of long-acting or oral PrEP and PEP within the community-based delivery of SRH services will overcome the challenges and barriers to effective use of oral daily PrEP and lead to a population-level effect on uptake and retention on PrEP and thus the prevalence of sexually transmissible HIV amongst 15-30 year olds living in rural KwaZulu-Natal, South Africa.

开始日期2024-02-27

申办/合作机构-

NCT06807736

/ RecruitingN/AIIT

PrEPared to Choose (PtC): an Implementation Study of the Delivery of Cabotegravir Long-acting Injectable Pre-exposure Prophylaxis (PrEP) As an HIV Prevention Product Option Within a PrEP Choice Context in a Real World Setting in Cape Town.

The goal of this clinical trial is to offer adolescents and young people in Cape Town, South Africa different HIV pre-exposure prophylaxis (PrEP) products and describe how they use these products over an 18-month period. The study has both clinical and implementation primary aims. The primary clinical aim is short and long-term persistence on PrEP. Persistence is defined as the length of time that a participant shows continuous use of a PrEP product as intended, without stopping PrEP or switching to another PrEP product. The primary implementation aim involves the determination of factors that either enable or serve as a barrier to PrEP uptake and continuation.
Participants will be offered a choice between three antiretroviral-containing PrEP products: (1) a Tenofovir-based oral tablet that needs to be taken daily; (2) a vaginal ring containing Dapivirine that provides HIV protection for up to one month; and (3) an intramuscular injection containing Cabotegravir that provides HIV protection for up to two months. Participants will be able to use the same product throughout the study, switch between products, or stop and restart on PrEP at any point.
The study will be offered from two study sites: the first is a mobile clinic that rotates on a fixed schedule across the study area and the second is a fixed-location government primary healthcare clinic. The study will be open to confirmed HIV-negative individuals, including adolescent girls and young women (aged 15-29 years), young gender and sexually diverse populations aged 15-29 years (including men who have sex with men, transgender people, and non-binary people), and their collective sexual partners (including heterosexual, cisgender men) of any age.

开始日期2024-02-13

申办/合作机构

Desmond Tutu Hiv Foundation

[+2]

NCT05416021

/ Completed临床1期

A Phase I, Open-Label, Randomized, Crossover Trial to Investigate the Relative Bioavailability of the 25 mg Dapivirine Vaginal Ring-004 Inserted Every 30 Days and 100 mg DPV Ring-008 Inserted for 90 Days in Healthy Female Participants

A Phase I, Open-Label, Randomized, Crossover Trial to Investigate the Relative Bioavailability of the 25 mg Dapivirine Vaginal Ring-004 inserted every 30 days and 100 mg Dapivirine Vaginal Ring-008 inserted for 90 days in Healthy Female Participants

开始日期2022-08-01

申办/合作机构

INC Research Holdings, Inc.

100 项与 Dapivirine 相关的临床结果

登录后查看更多信息

100 项与 Dapivirine 相关的转化医学

登录后查看更多信息

100 项与 Dapivirine 相关的专利（医药）

登录后查看更多信息

376

项与 Dapivirine 相关的文献（医药）

2025-03-01·INTERNATIONAL JOURNAL OF STD & AIDS

Understanding the sources of efficacy dilution in a trial of a monthly dapivirine vaginal ring for HIV-1 prevention

Article

作者: Peebles, Kathryn ; Brown, Elizabeth R ; Baeten, Jared M ; Palanee-Phillips, Thesla ; Matrajt, Laura

Introduction:

Women-initiated HIV – 1 prevention products are key to reducing women’s HIV-1 risk. Clinical trials of vaginal microbicides have shown limited to no efficacy in intention-to-treat (ITT) analyses. It is hypothesized that these negative results are partly due to efficacy dilution.

Methods:

We developed a microsimulation model of MTN-020/ASPIRE, a phase 3 trial that evaluated monthly use of a dapivirine vaginal ring for HIV-1 prevention. We evaluated four sources of efficacy dilution: trial-level factors: (i) an imbalance in the number of monthly sex acts between study arms and (ii) heterogeneity in risk emergent over time; and individual-level factors: (iii) product non-adherence and (iv) receptive anal intercourse.

Results:

Assuming 70% per-vaginal exposure efficacy (consistent with the ITT estimate of 27%), heterogeneity in risk accounted for the largest proportion of efficacy dilution, at 42% (90% CrI: 38, 45), followed by non-adherence (33%; 90% CrI: 27, 39), an imbalance in arms (18%; 90% CrI: 16, 21) and lastly, anal intercourse with less than 10% of efficacy dilution.

Conclusion:

Our results suggest that heterogeneity in risk was the most important source of efficacy dilution in the ASPIRE trial. Future trials of HIV-1 prevention products for women should consider alternative trial designs and analytic approaches that minimize bias introduced by heterogeneity in risk.

2025-01-27·Annual Review of Medicine

Update on HIV Chemoprevention

Review

作者: Blair, Cheríe S. ; Cambou, Mary Catherine ; Landovitz, Raphael J.

Despite rapid advances in the field of HIV prevention and treatment, unacceptably high global HIV incidence rates highlight the ongoing need for effective HIV prevention interventions for populations at risk for HIV acquisition. This article provides an updated review of the current data surrounding HIV prevention strategies, including treatment as prevention (TasP), preexposure prophylaxis (PrEP), and postexposure prophylaxis (PEP), as well as advances in sexually transmitted infection biomedical prevention. This review provides an overview of the multiple PrEP modalities that are available globally, such as oral PrEP, injectable cabotegravir, and the dapivirine vaginal ring, and describes their respective clinical trials, efficacies, and regulatory approvals. We also discuss ongoing research into novel PrEP agents, such as broadly neutralizing antibodies, and efforts toward HIV vaccine development.

2025-01-01·ARCHIV DER PHARMAZIE

6‐aryloxy‐2‐aminopyrimidine‐benzonitrile hybrids as anti‐infective agents: Synthesis, bioevaluation, and molecular docking

Article

作者: Bollikanda, Rakesh K. ; Devendra, Nagineni ; Bangalore, Pavan K. ; Kantevari, Srinivas ; Pranathi, Abburi Naga ; Sridhar, Balasubramanian ; Mikhalsky, Mikhail G. ; Niukalova, Maria A. ; Esaulkova, Iana L. ; Zarubaev, Vladimir V.

Abstract:

This report explores the potential of novel 6‐aryloxy‐2‐aminopyrimidine‐benzonitrile scaffolds as promising anti‐infective agents in the face of the increasing threat of infectious diseases. Starting from 2‐amino‐4,6‐dichloropyrimidine, a series of 24 compounds inspired from the antiviral drugs dapivirine, etravirine, and rilpivirine were designed and synthesized via a two‐step reaction sequence in good yields. Biological testing of synthetic analogs revealed potent inhibition against both viral and tuberculosis targets. Notably, compounds 5p (2,4‐dimethyl substitution; IC50 = 44 ± 4.9 µM; selectivity index [SI] = 20) and 5 s (3‐thiophenphenyl; IC50 = 6 ± 1 µM; SI = 120) showed significant antiviral activity against pandemic influenza virus A/Puerto Rico/8/34 (H1N1) with positive toxicity profiles and also exhibited good IC50 values (5p, IC50 = 10 ± 2 µM; SI = 9 and 5 s, IC50 = 16 ± 2 µM; SI = 60) against the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) (Wuhan strain) compared with favipiravir. In addition, analogs 5a, 5r, 5t, and 5u showed good antitubercular activity against Mycobacterium tuberculosis H37Rv strain and compounds 3, 5f, 5n, and 5q showed moderate antibacterial activity against gram+ve and gram‐ve bacterial strains, suggesting that this scaffold has a broad spectrum of therapeutic effects.

项与 Dapivirine 相关的新闻（医药）

2023-01-18

·PipelineReview

Janssen and Global Partners to Discontinue Phase 3 Mosaico HIV Vaccine Clinical Trial

Independent, scheduled review of Phase 3 Mosaico study finds investigational vaccine regimen lacks efficacy in preventing HIV No vaccine-related safety issues identified LEIDEN, THE NETHERLANDS I January 18, 2023 I The Janssen Pharmaceutical Companies of Johnson & Johnson, together with a consortium of global partners, today announced the results of an independent, scheduled data review of the Phase 3 Mosaico study (also known as HPX3002/HVTN706) of Janssen’s investigational HIV vaccine regimen. The study’s independent Data and Safety Monitoring Board (DSMB) determined that the regimen was not effective in preventing HIV infection compared to placebo among study participants. No safety issues with the vaccine regimen were identified. In light of the DSMB’s determination, the Mosaico clinical trial will be discontinued. Participant notifications and further analyses of the data are underway. Throughout the trial, study investigators have ensured that any individuals who contracted HIV received prompt HIV treatment and care. “We are disappointed with this outcome and stand in solidarity with the people and communities vulnerable to and affected by HIV,” said Penny Heaton, M.D., Global Therapeutic Area Head, Vaccines, Janssen Research & Development, LLC. “Though there have been significant advances in prevention since the beginning of the global epidemic, 1.5 million people acquired HIV in 2021 alone, underscoring the high unmet need for new options and why we have long worked to tackle this global health challenge. We remain steadfast in our commitment to advancing innovation in HIV, and we hope the data from Mosaico will provide insights for future efforts to develop a safe and effective vaccine. We are grateful to our Mosaico partners and the study investigators, staff and participants.” About the Phase 3 Mosaico Study Mosaico, a Phase 3 study of Janssen’s investigational HIV vaccine regimen, began in 2019, and completed vaccinations in October 2022. The study included approximately 3,900 cisgender men and transgender people who have sex with cisgender men and/or transgender people, who represent groups and populations vulnerable to HIV, at over 50 trial sites in Argentina, Brazil, Italy, Mexico, Peru, Poland, Puerto Rico, Spain and the United States. The study evaluated an investigational vaccine regimen containing a mosaic-based adenovirus serotype 26 vector (Ad26.Mos4.HIV) administered during four vaccination visits over one year. A mix of soluble proteins (Clade C/Mosaic gp140, adjuvanted with aluminum phosphate) was also administered at visits three and four. The Mosaico DSMB analysis, based on the data available to date, indicated that the regimen does not protect against HIV and the study is not expected to meet its primary endpoint. No safety issues with the vaccine regimen were identified. In light of this, the study will be discontinued, and further analyses are underway. The DSMB’s determination follows the primary analysis of the Phase 2b Imbokodo study, which was announced in August 2021 and found that a similar investigational HIV vaccine regimen did not provide sufficient protection against HIV in a population of young women in sub-Saharan Africa. The investigational vaccine regimen used in the Imbokodo study was found to have a favorable safety profile. The Mosaico study was led by a global public-private partnership including the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), the HIV Vaccine Trials Network (HVTN), the U.S. Army Medical Research and Development Command (USAMRDC), and Janssen Vaccines & Prevention B.V. Since 2005, Janssen Vaccines & Prevention B.V. has been participating as a sub-grantee in the NIH-supported Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) program under grants AI066305, AI078526, AI096040 and AI128751 (Principal Investigator, Prof. Dan Barouch). Johnson & Johnson’s Commitment to HIV Johnson & Johnson has been committed to the fight against HIV for decades, playing a key role in bringing nine therapeutics to people living with HIV and continuing to drive innovation in HIV prevention and care. In January 2021, the dapivirine ring, a discreet long-acting HIV prevention method specifically developed for women by the International Partnership for Microbicides (IPM) and based on Janssen’s compound, was recommended by the World Health Organization as an additional prevention choice for women with a substantial chance of contracting HIV as part of combination prevention approaches. In July 2021 , Zimbabwe became the first country to approve the use of the dapivirine ring among women ages 18 and older, with South Africa following suit in March 2022 . Additional regulatory decisions are pending. Johnson & Johnson also works with vulnerable communities on the frontlines of the HIV epidemic, and has supported collaborative initiatives like the DREAMS Partnership in sub-Saharan Africa, the MenStar Coalition , and the New Horizons Collaborative . To learn more about Johnson & Johnson’s commitment to combatting HIV, please visit jnj.com/hiv . About Johnson & Johnson At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities, and forward progress. That’s why for more than 135 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest diversified healthcare products company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body, and environment within reach of everyone, everywhere. We are blending our heart, science, and ingenuity to profoundly change the trajectory of health for humanity. About the Janssen Pharmaceutical Companies of Johnson & Johnson At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular, Metabolism & Retina; Immunology; Infectious Diseases & Vaccines; Neuroscience; Oncology; and Pulmonary Hypertension. Learn more at http://www.janssen.com and follow us at http://www.twitter.com/JanssenGlobal and www.twitter.com/JanssenUS . Janssen Vaccines & Prevention, B.V. and Janssen Research & Development, LLC are part of the Janssen Pharmaceutical Companies of Johnson & Johnson. SOURCE: Johnson & Johnson

疫苗临床2期临床3期临床结果

2023-01-18

·Johnson & Johnson

Janssen and Global Partners to Discontinue Phase 3 Mosaico HIV Vaccine Clinical Trial

LEIDEN, THE NETHERLANDS, (January 18, 2023) – The Janssen Pharmaceutical Companies of Johnson & Johnson, together with a consortium of global partners, today announced the results of an independent, scheduled data review of the Phase 3 Mosaico study (also known as HPX3002/HVTN706) of Janssen’s investigational HIV vaccine regimen. The study’s independent Data and Safety Monitoring Board (DSMB) determined that the regimen was not effective in preventing HIV infection compared to placebo among study participants. No safety issues with the vaccine regimen were identified.In light of the DSMB’s determination, the Mosaico clinical trial will be discontinued. Participant notifications and further analyses of the data are underway. Throughout the trial, study investigators have ensured that any individuals who contracted HIV received prompt HIV treatment and care.“We are disappointed with this outcome and stand in solidarity with the people and communities vulnerable to and affected by HIV,” said Penny Heaton, M.D., Global Therapeutic Area Head, Vaccines, Janssen Research & Development, LLC. “Though there have been significant advances in prevention since the beginning of the global epidemic, 1.5 million people acquired HIV in 2021 alone, underscoring the high unmet need for new options and why we have long worked to tackle this global health challenge. We remain steadfast in our commitment to advancing innovation in HIV, and we hope the data from Mosaico will provide insights for future efforts to develop a safe and effective vaccine. We are grateful to our Mosaico partners and the study investigators, staff and participants.”About the Phase 3 Mosaico StudyMosaico, a Phase 3 study of Janssen’s investigational HIV vaccine regimen, began in 2019, and completed vaccinations in October 2022. The study included approximately 3,900 cisgender men and transgender people who have sex with cisgender men and/or transgender people, who represent groups and populations vulnerable to HIV, at over 50 trial sites in Argentina, Brazil, Italy, Mexico, Peru, Poland, Puerto Rico, Spain and the United States.The study evaluated an investigational vaccine regimen containing a mosaic-based adenovirus serotype 26 vector (Ad26.Mos4.HIV) administered during four vaccination visits over one year. A mix of soluble proteins (Clade C/Mosaic gp140, adjuvanted with aluminum phosphate) was also administered at visits three and four.The Mosaico DSMB analysis, based on the data available to date, indicated that the regimen does not protect against HIV and the study is not expected to meet its primary endpoint. No safety issues with the vaccine regimen were identified. In light of this, the study will be discontinued, and further analyses are underway.The DSMB’s determination follows the primary analysis of the Phase 2b Imbokodo study, which was announced in August 2021 and found that a similar investigational HIV vaccine regimen did not provide sufficient protection against HIV in a population of young women in sub-Saharan Africa. The investigational vaccine regimen used in the Imbokodo study was found to have a favorable safety profile.The Mosaico study was led by a global public-private partnership including the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), the HIV Vaccine Trials Network (HVTN), the U.S. Army Medical Research and Development Command (USAMRDC), and Janssen Vaccines & Prevention B.V. Since 2005, Janssen Vaccines & Prevention B.V. has been participating as a sub-grantee in the NIH-supported Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) program under grants AI066305, AI078526, AI096040 and AI128751 (Principal Investigator, Prof. Dan Barouch).Johnson & Johnson’s Commitment to HIVJohnson & Johnson has been committed to the fight against HIV for decades, playing a key role in bringing nine therapeutics to people living with HIV and continuing to drive innovation in HIV prevention and care.In January 2021, the dapivirine ring, a discreet long-acting HIV prevention method specifically developed for women by the International Partnership for Microbicides (IPM) and based on Janssen’s compound, was recommended by the World Health Organization as an additional prevention choice for women with a substantial chance of contracting HIV as part of combination prevention approaches. In July 2021, Zimbabwe became the first country to approve the use of the dapivirine ring among women ages 18 and older, with South Africa following suit in March 2022. Additional regulatory decisions are pending.Johnson & Johnson also works with vulnerable communities on the frontlines of the HIV epidemic, and has supported collaborative initiatives like the DREAMS Partnership in sub-Saharan Africa, the MenStar Coalition, and the New Horizons Collaborative.To learn more about Johnson & Johnson’s commitment to combatting HIV, please visit jnj.com/hiv.About Johnson & JohnsonAt Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities, and forward progress. That’s why for more than 135 years, we have aimed to keep people well at every age and every stage of life. Today, as the world’s largest diversified healthcare products company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body, and environment within reach of everyone, everywhere. We are blending our heart, science, and ingenuity to profoundly change the trajectory of health for humanity.About the Janssen Pharmaceutical Companies of Johnson & JohnsonAt Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular, Metabolism & Retina; Immunology; Infectious Diseases & Vaccines; Neuroscience; Oncology; and Pulmonary Hypertension.Learn more at http://www.janssen.com and follow us at http://www.twitter.com/JanssenGlobal and www.twitter.com/JanssenUS. Janssen Vaccines & Prevention, B.V. and Janssen Research & Development, LLC are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.Cautions Concerning Forward-Looking StatementsThis press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding Janssen’s investigational, mosaic-based HIV vaccine regimen. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Vaccines & Prevention, B.V., the Janssen Pharmaceutical Companies, and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: the potential that the expected benefits and opportunities of the agreement may not be realized or may take longer to realize than expected; challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 2, 2022, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Report on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of Janssen Vaccines & Prevention, B.V., the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

疫苗临床2期临床3期临床结果

100 项与 Dapivirine 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11246	Dapivirine	G01AX17	DB08639

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
HIV感染	临床3期	肯尼亚	International Partnership for Microbicides	2011-07-01
HIV感染	临床3期	卢旺达	International Partnership for Microbicides	2011-07-01
获得性免疫缺陷综合征	临床2期	南非	INC Research Holdings, Inc.	2009-07-01
获得性免疫缺陷综合征	临床2期	南非	International Partnership for Microbicides	2009-07-01
避孕	临床1期	美国	International Partnership for Microbicides	2018-07-17
阴茎硬结	临床1期	美国	INC Research Holdings, Inc.	2011-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01617096 (MTN-020/ASPIRE, Pubmed \| J Infect Dis)	临床3期	HIV感染	-	Dapivirine Vaginal Ring	鏇鬱網鑰鹹齋觸夢鬱鏇(衊襯襯範廠廠簾範憲構) = 艱蓋積獵鹽壓構艱襯窪繭衊膚糧鏇選構選獵觸 (鏇艱壓憲築廠夢夢製選, 1.8 ~ 3.1)	积极	2024-04-12
				Placebo	鏇鬱網鑰鹹齋觸夢鬱鏇(衊襯襯範廠廠簾範憲構) = 鏇網鹹遞憲鹹艱築壓顧繭衊膚糧鏇選構選獵觸 (鏇艱壓憲築廠夢夢製選, 2.9 ~ 4.4)
NCT01617096 (MTN-020/ASPIRE \| ASPIRE \| MTN-020, CTgov)	临床3期	HIV感染	2,629	Dapivirine Vaginal Ring (Dapivirine Vaginal Ring)	鹽獵鬱鬱鹽積鬱遞餘鏇(顧糧衊夢糧築網繭獵鬱) = 膚獵膚窪夢遞構鬱糧齋淵鑰簾獵鹹顧鬱蓋糧醖 (構醖襯襯鏇觸窪衊襯膚, 築鏇窪製壓齋淵選願積 ~ 鏇獵憲膚鹽範獵獵積衊) 更多	-	2022-12-16
				Placebo Ring (Placebo Ring)	鹽獵鬱鬱鹽積鬱遞餘鏇(顧糧衊夢糧築網繭獵鬱) = 鏇齋廠網鹽鑰蓋鬱簾鏇淵鑰簾獵鹹顧鬱蓋糧醖 (構醖襯襯鏇觸窪衊襯膚, 構鏇襯艱衊廠鏇憲顧製 ~ 艱積鏇糧範餘選簾衊糧) 更多
NCT02862171 \| NCT01539226 (The Ring Study and DREAM, Pubmed)	临床3期	HIV感染	-	Dapivirine Vaginal Ring-004 (DVR)	淵窪遞夢鏇糧選夢顧積(鹹廠淵網繭簾鹹淵糧願) = 窪簾製鑰範積製齋餘構糧夢積淵窪選壓糧鏇膚 (網艱壓廠膚蓋艱網鹹鏇 )	-	2022-11-08
NCT02862171 (DREAM, CTgov)	临床3期	HIV感染	941	Dapivirine Vaginal Ring-004	壓膚衊窪齋築醖觸範遞(艱餘齋窪簾鬱淵築鏇鹹) = 獵窪壓構糧築餘鹹構顧衊窪願廠糧範廠簾淵艱 (齋製窪淵淵遞艱鹹夢遞, 壓醖製窪範遞憲齋艱齋 ~ 鹹範蓋鏇鹹簾繭淵簾糧) 更多	-	2022-10-25
NCT02858037 (HOPE, CTgov)	临床3期	HIV感染	1,456	Dapivirine Vaginal Ring	鏇糧網餘鹹衊願齋觸鬱(選網積壓顧衊衊齋憲壓) = 蓋構鏇積鬱簾顧繭膚範鹽簾網築淵醖鬱範築憲 (壓憲夢顧遞鹽鑰獵顧艱, 鏇範齋遞鏇遞憲遞餘範 ~ 廠網衊築齋網廠壓衊遞) 更多	-	2022-10-25
NCT00799058 (CTgov)	临床1/2期	HIV感染	128	dapivirine gel 4759 (Dapivirine Gel 4759)	夢糧鬱鏇願築衊構製壓(範顧齋鏇糧鑰鹹憲觸顧) = 鏇夢鑰齋獵鏇艱繭製夢網壓憲鹽選觸獵壓糧糧 (壓衊網憲鬱製鑰簾積醖, 積獵餘糧遞築齋艱遞繭 ~ 鬱鏇範顧廠餘艱構窪鏇) 更多	-	2022-10-25
				dapivirine 4789 (Dapivirine Gel 4789)	夢糧鬱鏇願築衊構製壓(範顧齋鏇糧鑰鹹憲觸顧) = 觸築廠窪網遞廠範鏇網網壓憲鹽選觸獵壓糧糧 (壓衊網憲鬱製鑰簾積醖, 襯膚獵遞襯齋顧範鏇齋 ~ 築衊襯獵願築窪醖簾積) 更多
NCT02028338 (CTgov)	临床2期	HIV感染	96	dapivirine ring (Dapivirine Ring)	廠願夢製簾構壓構壓壓(鏇積糧構繭鬱構鹽廠衊) = 襯構鏇選範簾網糧繭網齋製構膚顧選廠鬱選鬱 (廠蓋積艱艱艱糧鏇鹹積, 鏇糧襯憲醖顧構齋鏇顧 ~ 鹹夢網鏇遞繭壓範簾範) 更多	-	2022-10-24
				placebo ring (Placebo Ring)	廠願夢製簾構壓構壓壓(鏇積糧構繭鬱構鹽廠衊) = 齋鑰願積壓繭鬱夢糧淵齋製構膚顧選廠鬱選鬱 (廠蓋積艱艱艱糧鏇鹹積, 壓鑰淵襯繭齋襯顧膚獵 ~ 製鏇網蓋積襯築繭糧廠) 更多
NCT02010593 (CTgov)	临床2期	HIV感染	96	Dapivirine Vaginal Ring (Dapivirine Vaginal Ring)	獵鑰網簾窪衊鑰窪醖築(衊鬱衊築鹽鬱憲網觸糧) = 衊夢簾鏇積醖鬱網艱網製糧廠鏇夢艱壓鹹鏇鹽 (壓獵廠鬱製衊膚網願構, 願窪鹽憲鏇網廠構壓糧 ~ 艱構顧淵窪夢壓蓋願鑰) 更多	-	2022-10-05
				Placebo Vaginal Ring (Placebo)	獵鑰網簾窪衊鑰窪醖築(衊鬱衊築鹽鬱憲網觸糧) = 鏇顧餘選範遞衊鹽夢遞製糧廠鏇夢艱壓鹹鏇鹽 (壓獵廠鬱製衊膚網願構, 餘簾齋廠鹹築簾夢鑰範 ~ 壓衊鑰鑰鏇餘鹹艱淵製) 更多
NCT03234400 (Pubmed) 人工标引	临床1期	HIV感染	49	dapivirine (extended duration arms)	淵窪壓襯醖膚蓋選選範(艱選顧醖艱簾鏇醖範鹽) = There were no differences in the proportion of participants with grade ≥2 genitourinary AEs or grade ≥3 AEs in the extended duration versus monthly ring arms 鏇襯顧遞淵顧鹽蓋鏇網 (願憲餘壓憲襯鏇獵簾願 )	积极	2021-06-01
				dapivirine (monthly ring arms)
NCT02862171 (DREAM, Pubmed \| Lancet HIV) 人工标引	临床3期	HIV感染	941	dapivirine	選艱鏇顧鹹衊範淵壓觸(窪鑰憲鑰壓襯鹽選夢願) = 夢廠夢鏇積築窪遞襯蓋鬱襯齋鏇築壓範夢積願 (蓋艱簾顧醖醖齋醖蓋築 ) 更多	积极	2021-02-01